CELC
Price
$11.02
Change
-$0.05 (-0.45%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
420.77M
25 days until earnings call
CLRB
Price
$0.31
Change
-$0.00 (-0.00%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
13.95M
13 days until earnings call
Ad is loading...

CELC vs CLRB

Header iconCELC vs CLRB Comparison
Open Charts CELC vs CLRBBanner chart's image
Celcuity
Price$11.02
Change-$0.05 (-0.45%)
Volume$1.24K
Capitalization420.77M
Cellectar Biosciences
Price$0.31
Change-$0.00 (-0.00%)
Volume$200
Capitalization13.95M
CELC vs CLRB Comparison Chart
Loading...
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELC vs. CLRB commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELC is a Buy and CLRB is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (CELC: $11.05 vs. CLRB: $0.31)
Brand notoriety: CELC and CLRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELC: 60% vs. CLRB: 39%
Market capitalization -- CELC: $420.77M vs. CLRB: $13.95M
CELC [@Biotechnology] is valued at $420.77M. CLRB’s [@Biotechnology] market capitalization is $13.95M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELC’s FA Score shows that 0 FA rating(s) are green whileCLRB’s FA Score has 0 green FA rating(s).

  • CELC’s FA Score: 0 green, 5 red.
  • CLRB’s FA Score: 0 green, 5 red.
According to our system of comparison, CELC is a better buy in the long-term than CLRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELC’s TA Score shows that 5 TA indicator(s) are bullish while CLRB’s TA Score has 6 bullish TA indicator(s).

  • CELC’s TA Score: 5 bullish, 3 bearish.
  • CLRB’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, CLRB is a better buy in the short-term than CELC.

Price Growth

CELC (@Biotechnology) experienced а +10.61% price change this week, while CLRB (@Biotechnology) price change was +9.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.07%. For the same industry, the average monthly price growth was -6.06%, and the average quarterly price growth was -12.59%.

Reported Earning Dates

CELC is expected to report earnings on Aug 07, 2025.

CLRB is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+7.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CELC($421M) has a higher market cap than CLRB($14M). CLRB YTD gains are higher at: 3.779 vs. CELC (-15.584). CLRB has higher annual earnings (EBITDA): -51.29M vs. CELC (-85.45M). CELC has more cash in the bank: 264M vs. CLRB (34.3M). CLRB has less debt than CELC: CLRB (513K) vs CELC (97.2M). CELC (0) and CLRB (0) have equivalent revenues.
CELCCLRBCELC / CLRB
Capitalization421M14M3,007%
EBITDA-85.45M-51.29M167%
Gain YTD-15.5843.779-412%
P/E RatioN/AN/A-
Revenue00-
Total Cash264M34.3M770%
Total Debt97.2M513K18,947%
FUNDAMENTALS RATINGS
CELC vs CLRB: Fundamental Ratings
CELC
CLRB
OUTLOOK RATING
1..100
113
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
60
Fair valued
PROFIT vs RISK RATING
1..100
79100
SMR RATING
1..100
9599
PRICE GROWTH RATING
1..100
6065
P/E GROWTH RATING
1..100
10066
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CELC's Valuation (47) in the Miscellaneous Commercial Services industry is in the same range as CLRB (60) in the Biotechnology industry. This means that CELC’s stock grew similarly to CLRB’s over the last 12 months.

CELC's Profit vs Risk Rating (79) in the Miscellaneous Commercial Services industry is in the same range as CLRB (100) in the Biotechnology industry. This means that CELC’s stock grew similarly to CLRB’s over the last 12 months.

CELC's SMR Rating (95) in the Miscellaneous Commercial Services industry is in the same range as CLRB (99) in the Biotechnology industry. This means that CELC’s stock grew similarly to CLRB’s over the last 12 months.

CELC's Price Growth Rating (60) in the Miscellaneous Commercial Services industry is in the same range as CLRB (65) in the Biotechnology industry. This means that CELC’s stock grew similarly to CLRB’s over the last 12 months.

CLRB's P/E Growth Rating (66) in the Biotechnology industry is somewhat better than the same rating for CELC (100) in the Miscellaneous Commercial Services industry. This means that CLRB’s stock grew somewhat faster than CELC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELCCLRB
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 21 days ago
88%
Bearish Trend 9 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCTGX24.45N/A
N/A
Fidelity Advisor Small Cap Growth M
GTSIX27.08N/A
N/A
Invesco Small Cap Growth Inv
TVRIX16.20N/A
N/A
NAA Allocation Fund Institutional
EMQIX7.87N/A
N/A
Ashmore Emerging Markets Active Eq Instl
GQJIX10.86N/A
N/A
GQG Partners Intl Qual Val Fd Ins

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been loosely correlated with PRME. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CELC jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
-0.63%
PRME - CELC
46%
Loosely correlated
+4.14%
ABOS - CELC
44%
Loosely correlated
+3.86%
CLDX - CELC
44%
Loosely correlated
+0.23%
ELVN - CELC
43%
Loosely correlated
-1.45%
NUVB - CELC
42%
Loosely correlated
+0.97%
More

CLRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLRB has been closely correlated with QTTB. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if CLRB jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLRB
1D Price
Change %
CLRB100%
+2.48%
QTTB - CLRB
77%
Closely correlated
-1.05%
ADCT - CLRB
47%
Loosely correlated
+4.88%
ANAB - CLRB
45%
Loosely correlated
-5.47%
IBRX - CLRB
39%
Loosely correlated
-0.37%
CELC - CLRB
37%
Loosely correlated
-0.63%
More